CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.

1:14-cv-01043

Overview

Case Number 1:14-cv-01043
Filing Date 2014-08-13
Status Terminated
Termination Date 2019-03-27
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Breckenridge Pharmaceutical Inc. Operating Company

Represented By

6 Attorneys Listed

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Selena E. Molina

Delaware Court of Chancery

Tel: +1 (302) 421-6829

Delaware Court of Chancery, 500 North King Street

Matthew L. Fedowitz

Email: matthew.fedowitz@bipc.com

Daniel R. Evans

Email: devans@merchantgould.com

Bruce J. Boggs

Email: jboggs@merchantgould.com

Kelly E. Farnan

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7705

Richards, Layton & Finger, PA, One Rodney Square

Plaintiff

Novartis AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

7 Attorneys Listed

Nicholas N. Kallas

Email: nkallas@venable.com

Laura K. Fishwick

Email: lfishwick@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Corinne E. Atton

Email: catton@venable.com

Christopher E. Loh

Email: cloh@venable.com

Christina Schwarz

Email: cschwarz@venable.com

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 6 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (6 found):
PTAB: 6
USPTO PTAB Trial 2016-05-26
IPR2016-01103

Breckenridge Pharmaceutical, Inc. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-26
IPR2016-01102

Roxane Laboratories, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2016-05-17
IPR2016-01059

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-10
IPR2016-01023

BRECKENRIDGE PHARMACEUTICAL, INC. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00084

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00078

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (6455518)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5665772
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Filed: 1993-09-24
Issued: 1997-09-09
Expired (Term Ended) +2176d PTA
Expires: 2019-09-09
US6004973
Pharmaceutical compositions comprising rafamycin coprecipitates
Filed: 1996-07-12
Issued: 1999-12-21
Expired (Term Ended)
Expires: 2016-07-12
US6239124
Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
Filed: 1997-07-29
Issued: 2001-05-29
Expired (Term Ended) +13d PTA
Expires: 2017-08-11
US6455518
Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
Filed: 2001-01-11
Issued: 2002-09-24
Expired (Term Ended)
Expires: 2021-01-11

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+2176 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 1 Claim Construction / Markman Filing 1

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Pending / Under Review
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 9/4/2015. Amended Pleadings due by 9/4/2015....
Entry #18 • 2015-01-15 Document →
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME Answer to Complaint to through and including November 12, 2014 - filed by Breckenridge Pharmaceutical Inc.. (Farnan, Kelly) (Entered:...
Entry #9 • 2014-10-09 Document →

Docket Entries

(25 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1570002.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dmp, ) (Entered: 08/13/2014)

Entry #1 • 2014-08-13
1
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1570002.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dmp, ) (Entered: 08/13/2014)

Entry #1 • 2014-08-13
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1570002.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dmp, ) (Entered: 08/13/2014)

Entry #1 • 2014-08-13
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1570002.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dmp, ) (Entered: 08/13/2014)

Entry #1 • 2014-08-13
2
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1570002.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dmp, ) (Entered: 08/13/2014)

Entry #1 • 2014-08-13
2

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc